Allakos Inc. is focused on developing innovative therapeutics that target immunomodulatory receptors on immune effector cells, particularly in the context of allergy, inflammatory, and proliferative diseases. Their lead program centers around AK006, a therapeutic antibody designed to inhibit mast cells, which are known to play a significant role in various inflammatory conditions. AK006 specifically targets Siglec-6, an inhibitory receptor found on mast cells, and has been engineered to enhance its effectiveness by increasing the duration it remains on the cell surface. This approach not only aims to inhibit mast cell activation but also to reduce mast cell numbers through mechanisms such as antibody-dependent cellular phagocytosis (ADCP).

The clinical development of AK006 is currently underway, with studies being conducted in healthy volunteers and plans to initiate a Phase 1 trial for Chronic Spontaneous Urticaria (CSU) in the near future. The company is exploring multiple potential indications within inflammation and immunology, leveraging the unique properties of AK006 to address diseases where mast cells are implicated in the pathology. Allakos Inc. is also investigating the broader implications of Siglec receptors, including Siglec-8, in regulating mast cell function and their potential as therapeutic targets for various allergic and inflammatory diseases.

United States

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

Allergy

Digestive System Diseases

Immune System Diseases

Inflammatory disorders

Allakos Inc

Eosinophilic Esophagitis

Lirentelimab has demonstrated positive clinical activity in diseases &nbsp;thought to be driven by mast cells and eosinophils (e.g., eosinophilic &nbsp;esophagitis, eosinophilic gastritis and/or eosinophilic duodenitis) and &nbsp;diseases believed to be driven by mast cells only (e.g., chronic &nbsp;urticaria, indolent systemic mastocytosis). Clinical and preclinical &nbsp;results demonstrate that lirentelimab broadly inhibits mast cells and &nbsp;rapidly depletes eosinophils. In addition, patients treated with &nbsp;lirentelimab in clinical studies reported improvement in &nbsp;disease&nbsp;symptoms.
<a href="https://www.allakos.com/clinical/">Source</a>

Lirentelimab (AK002) (Siglec-8)

Chronic urticaria

Lirentelimab (AK002) (Siglec-8) 

Eosinophilic Duodentitis

Eosinophilic Gastritis

Atopic dermatitis

Lirentelimab (AK002) 

Chronic spontaneous urticaria

AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. In pre-clinical studies, AK006 appears to provide deeper mast cell inhibition than lirentelimab and, in addition to its inhibitory activity, reduce mast cell numbers.

Allakos Inc

Company Details